Are you using the right tumor micro environment model? Cancer is a disease of aging @sitcancer.bsky.social #SITC25 great session at the annual meeting on the aged immune system and the tumor micro environment moderated by Drs DA and A Weeraratna.

Great session exploring neuro-immunology in cancer immunotherapy #SITC25. Clearly we have much to learn about this little studied part of tumor biology. U Von Adrian demonstrated how afferent neurons organize and activate MDSCs at the tumor site @sitcancer.bsky.social

Excited to present our work at SITC this weekend! Join us on Saturday for Ryma Toumi's poster #796: Engineering T cells to reprogram inhibitory macrophages #SITC2025 #CancerResearch

Hill Day @sitcancer.bsky.social sharing our support for the NIH and immunotherapy for cancer w Dr Robyn Gartrell and Andrew Donlon from Rep McClain Delaney’s House Office. Thanks also to staffers from Sen Van Hollen and Alsobrooks office for hosting us as well.

Our science at SITC -2 abstracts in the top 150 #Miltenyi #SITC25 #SITC2025 MSLN armored CAR-T (208), PSMA armored CAR-T (228) Spatial proteomics of post Tx sarcoma (243) CD5 CAR-NK (252) BCMA bi-paratopic CAR-T (292) CD276 CAR-T fitness (295) hypoxia expanded NK cells (390) @sitcancer.bsky.social

Leroy Hood holds forth on the future of genomics and phenomics. Just as we only now have incorporated epigenomics into human biology- there is likely still missing major data sets to allow new advances to come. i e. one proteins can be modified 400 different ways. @systemsbiology.bsky.social

The CAR-T therapy team at Taichung medical center in Taiwan - amazing world class work. This includes new CARs from #Miltenyi, Novartis Tcharge for autoimmune disease and a robust regenerative medicine program

#UNGA80 #ECSA East, Central, Southern Africa Session at the UN General Assembly Mtg #ScienceDiplomacy chair Prof Ntobeko Ntusi looking to bridge divides through shared knowledge and establishing regional centers of excellence. We are here to advocate for global health for the UN Pact for the Future

Having visited private and public institutes (view is the medical school at Albert Einstein SOM in São Paulo)- I am inspired by the new approaches for cell and gene therapy. Most of the world has looked at what our “market” has produced and is creating affordable alternatives

No one, at this point, is stupid and venal enough to take the administration up on this - right?

Dr Hanahan wins the Pezcoller! #AACR25 @theaacr.bsky.social and published today the IL-1 signature of tumors induces systemic immunosuppression_ and is reversed by anti- IL-RAP antibody.

Wonderful overview today by Ken Anderson @theaacr.bsky.social #AACR25 of the advances in MM- adding CARs to degraders (imids) and blockers (bortezomib) both of which also have immune activity has completely changed the outlook for patients- and that’s why we are here

We owe him much for his leadership at CBER during a period of remarkable therapeutic advances. The havoc caused by this administration will have a devastating impact for years. www.washingtonpost.com/politics/202...

At 9 yrs old, my granddaughter was diagnosed with DIPG. It is terminal, usually within 9 months. Because of Dr. Vitanza at Seattle Children’s and clinical trials, we had her mostly symptom free for about 32 months. Make these cuts make sense! I am outraged!

Engaging talk by Jen Adair @fredhutch.bsky.social Tandem2025 @astct.bsky.social on efforts to make cell and gene therapy available in low and middle income countries. Academic centers need to step up. Great to see my friend @cgtgaithersburg.bsky.social in the Global Gene Therapy Initiative

Dr S Davies from cincinnatichildren’s presents a challenge-using a new vector system and reduced intensity conditioning to keep #sicklecell therapy low cost by keeping the process in academic medical centers & not a strictly high-priced pharma product @ascaa.bsky.social @astct.bsky.social #Tandem25

Dr M Bleakly from @fredhutch.bsky.social delivering a master class on using minor antigens to create anti-leukemia T cells in the context of HSCT @astct.bsky.social #Tandem25 incredible analysis of hematologic restricted targets

Dr N Shah from MCW presenting Tandem CD20-19 CAR-T using fresh in/fresh out manufacturing allowing many patients to receive this therapy who otherwise would not qualify @astct.bsky.social #Tandem25

Defend the NIH. timmermanreport.com/2025/02/defe...

Stand Up for Science rallies will be held in DC and state capitals on March 7th. Share with friends. Sign-up here to get email updates with details: www.eventbrite.com/e/stand-up-f...

Michael Holmes presents wall shaking data showing in vivo gene therapy using #Tessera gene writers to cure sickle cell disease and create CARs directly in vivo in model systems #Tandem25

Andy Sharenberg #UmojaBio presents the direct in vivo platform to create CAR-T #Tandem2025

@lulii4.bsky.social love the 4

So-when is the March for Science? I only see references to the previous one. We can’t let NIH be run by political appointees. This is proposed at the institute level and will likely go much further. The war on DEI, the intimidation of our colleagues who are visa holders…we know why we should march

Some thoughts on the confusion and anxiety created by the current freeze on communications, hiring, grant reviews, travel, etc at NIH (gift link):

Damn. Trump hits NIH with ‘devastating’ freezes on meetings, travel, communications, and hiring. All study sections are halted. www.science.org/content/arti...

Our federal colleagues’ (NIH) communications are being actively monitored by the government. They have been told to inform on one another if there is any DEI activity. If you are a fed- go get a personal device now. You should have been using your own already.

Treatment-free remission in CML offers hope for sustainable recovery, aiming to make it a common pathway towards potential cures. by Hughes TP, Yong AS and Ross DM in Blood #MedSky 📖 read the article:

www.nature.com/articles/s41.... The new Brainchild publication for B7H3 CAR-T cell therapy for pediatric brain tumors. Surprising and encouraging that CNS tumors may be the next breakthrough in the field #seattlechildrens #UWpediatrics #DIPG #CARTcell #BTCCCR #immunotherapy

Nancy Goodman, founder and CEO of Kids v Cancer, told Newsweek the funding would go to critical research for pediatric cancer.

The durability of cure for ADA-SCID with lentiviral vectors is amazing. Rarity, a public benefit corp., has been formed to carry this therapy forward where previous models have failed #ASH24 Dr M Masiuk presented the plot below-one of many showing the durability of correction #kohnlab #rarity #CIRM

Dr I Odame sharing a vision to make high impact changes on sickle cell disease care in Africa that will scale #ASH24 Hydroxyurea access must be the cornerstone #CONSA #sicklecell

“Newborn screening combined with evidence based intervention saves lives!” #ASH24 session on challenges and opportunities in sickle cell care in Africa by Dr O Nnodu #CONSA #sicklecell #NHLBI

Mind-blowing results showing a ketogenic diet or just the metabolite BHB strongly activates CAR-T activity in mice #ASH24 @ruellalab.bsky.social data demonstrate nice impact on cellular respiration (OCR)

Dr Y Del-Adomakoh presents Hemoglobin SC (HbSC) disease study from Ghana and shows increased fetal globin, improved symptoms- although some DLTs were seen #ASH24 #sicklecell

#ASH24 #leusm Rao: COG study AALL1731 adding Blin to 1L therapy in children w standard risk (age <10, WBC <50) B-ALL. NGS MRD neg pts not randomized. Recent COG studies have failed for further improve outcomes in std and high risk B-ALL, suggesting ceiling reached with cytotoxic chemo.

If you cant be at ASH to see Seattle Children’s and Children’s Oncology Group own Rachel Rau it’s worth checking out the paper! Out today in the NEJM. Blina for the win! www.nejm.org/doi/full/10....

Dr P Rio from Rocket presenting #Fanconi anemia gene therapy #ASH24 without preconditioning therapy

Autolus’ CD22 CAR-T after CD19 therapy failure in adult DLBCL -CR 53% and 68% ORR, amazing response for this heavily pretreated population #ASH24 This year the maturity and effectiveness of the first generation of CAR-T therapies is clearly established. Let’s keep going and improve CAR-T even more

Tandem CD19-20 CAR-T cell (Zamto-cel) Phase II for DLBCL presented by Dr. N Shah of Medical College of Wisconsin shows fresh in and fresh out manufacturing is even faster! #ASH24

T-Charge Therapy (Rapcabtagene Autoleucel) presented by Dr Riedell from Univ. of Chicago #ASH24. Best CR of 65%. Looks durable and similar to current therapies- demonstrating that a 2 day process is possible for CAR-T. Importantly, lower dose LD may improve CR.

Gave a talk on social media this morning at #ASH24 Someone asked about the longevity of BlueSky and I answered optimistically. So don’t make me look dumb y’all.

The pioneers in Barcelona are at it again: now with point-of-care tandem vectors CD19/BCMA. Local manufacturing drives innovation. This is a really good pre-clinical manuscript for those interested in CAR formats #ASGCT #ASH2024 www.cell.com/molecular-th...

In revision but sharing the preprint of Seattle Children's completed first-in-human phase 1 #clinicaltrial of intracranial #B7-H3 #CARTcells for children with #DIPG. We hope this work solidifies the foundation of this #immunotherapy for children w/ #braintumors. #EndDIPG doi.org/10.21203/rs....